

NIDA Director's Report to the NIH Collaborative Research on Addiction (CRAN) Council


Nora D. Volkow, M.D.


Director

National Institute on Drug Abuse

National Institutes of Health

May 8, 2024





Iván D. Montoya, M.D., M.P.H.
Director
Division of Therapeutics and
Medical Consequences

2023 Monitoring the Future Study

Key Findings- Prevalence (2022 to 2023)

	8th	10th	12th		8th	10th	12th
Abstainers				Heroin			
Lifetime		+	+	Lifetime			-
Past Month			+	Past Year			-
LSD				Narcotics o/t Heroin			
Lifetime			-	Lifetime			-
Past Year			-	Past Year			-
Past Month			-	Oxycontin			
MDMA				Past Year		-	-
Lifetime			-	Vicodin			
Past Year			-	Past Year		-	-
Past Month			-	Amphetamines			
Cocaine				Past Year			-
Lifetime			-	Adderall			
Past Year			-	Past Year			-
Past Month			-	Sedatives			
Crack				Past Month			-
Lifetime			-	Tranquilizers			
Past Year			-	Past Year			-
Cocaine o/t Crack				Past Month			-
Lifetime			-				
Past Year		+	-				
Past Month		+	-				


	8th	10th	12th		8th	10th	12th
Alcohol				Vaping, Any			
Lifetime		-	-	Lifetime		-	-
Past Year			-	Past Year		-	
Past Month			-	Past Month		-	-
Daily			-	Vaping Nicotine			
10+ drinks row/2wks			-	Lifetime			-
Been Drunk				Past Year		-	-
Past Month			-	Past Month		-	-
Beer				Daily		-	
Lifetime	-			Snus			
Flavored Alc				Past Month	-		
Lifetime	-			Any Nicotine			
Alc Bev + Caff				Past Month		-	-
Past Year	+			Nicotine o/t Vaping			
Cigarettes				Past Month			-
Daily			-	Steroids			
1/2+ pack/day			-	Past Month			-
Reg little cigars/Cigarillos				Legal use of non-stim ADHD Rx			
Past Month		-		Current			-
Large Cigars							
Past Month		-					

2023 Monitoring the Future Study


Prevalence of Past Year Drug Use Among 12th graders

Drug	Prev.	Drug	Prev.
Alcohol	45.7	Hookah	2.7
* Vaping, Any	28.8	Cough Medicine*	2.4
Marijuana/Hashish	29.0	Amphetamines*	2.1
Vaping Nicotine	23.2	Inhalants	2.0
Vaping MJ	19.6	Sedative/Tranquilizers*	1.9
Alcohol w/ Caffeine	11.6	Snus	1.8
Delta-8	11.4	Adderall*	1.7
Small Cigars	4.4	LSD	1.2
* Hallucinogens	4.3	Narcotics o/t Heroin*	1.0
Hall other than LSD	4.0	Ketamine	1.0
Nicotine pouches	2.9	MDMA (Ecstasy)	0.7

Percent of Students Reporting Any Illicit Drug Use in Past Year, by Grade





Percent of Students Reporting Daily Use of Marijuana, by Grade



Past Month Substance Use: People Aged 12 or Older; 2022

Past Year Initiates of Substances: People Aged 12 or Older; 2022



Rx = prescription.

Note: The estimated numbers of past year users of different illicit drugs are not mutually exclusive because people could have used more than one type of illicit drug in the past year.


Brain Development and the Effects of ACE and Genetics

HEALthy Brain and Child Development (HBCD) Study





Longitudinal study of > 7000 infants to understand normative neurodevelopment from birth to 9-10 years and assess impact of in utero exposures to drugs and harmful environments

Adolescent Brain Cognitive Development (ABCD) Study



Longitudinal study of about 12,000 children from ages 9-10 through early adulthood to assess factors that influence individual brain development trajectories and functional outcomes



2022-2023: Provisional* Drug Overdose Deaths 12-months ending in select months

	ALL DRUGS	HEROIN	NAT & SEMI SYNTHETIC	METHADONE	SYNTHETIC OPIOIDS (illicit fentanyl)	COCAINE	OTHER PSYCHO-STIMULANTS (meth.)
11/2022*	110,063	6,198	12,197	3,426	75,418	27,991	35,001
5/2023*	113,127	5,170	11,695	3,514	78,947	30,346	37,141
11/2023*	109,527	4,249	10,448	3,396	76,303	30,326	36,836
Percent Change 11/22-11/23	-0.49%	-31.45%	-14.34%	-0.88%	1.17%	8.34%	5.24%


*NCHS Provisional drug-involved overdose death counts are PREDICTED VALUES, 12 months ending in select months. The numbers for 2022 differ from final data in slide 1 because provisional data includes all deaths that occurred in the US including foreign residents. Final data through 2022 on slide 1 is limited to deaths in U.S. residents.

<https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm>

Therapeutics For Polysubstances


- Overdose reversal agents from polysubstance use
- Pharmacological and biological agents for polysubstance use
- Device-based therapeutics for polysubstance use

Neuromodulation



Low Intensity Ultrasound


Psychedelics



GLP1-R agonists



Drug Overdose Death Rates by Race/Ethnicity



NCHS, National Vital Statistics System. Estimates for 2022 are based on provisional data.



Native Collective Research Effort to Enhance Wellness (N CREW)

Addressing Overdose, Substance Use & Pain



Timeline: OT Components

2 N CREW ROAs posted
(*Jun, FY23*)

ROA applications due
(*Nov, FY24*)

N CREW Review Meeting
(*Feb, FY24*)

T/NASO Developing, Planning, and Piloting of Research Projects
OT awards (*Jun, FY24*)

Native Research Resource Network OT awards (*Jun, FY24*)

June FY23

Nov FY24


Feb FY24

June FY24

FY 2023

FY 2024

Drug Overdose Death Rate, by Age Group






NCHS, National Vital Statistics System. *Estimates for 2022 are based on provisional data.

^Beginning in 2015, markings show statistically significant change compared with the previous year (95% CI's, p-value of 0.05).

Research Across the Cascade of Care for Substance Use Disorder

Novel harm reduction approaches	Understanding and addressing barriers
Novel settings for and modes of service delivery	Reaching understudied populations




Longitudinal (n=7,500 infants) normative neurodevelopment study from birth to 9-10 years to investigate impact of drug exposures and social determinants of health factors and genes throughout childhood

April 30, 2024

Libby March for The New York Times

- **Justice Dept. Plans to Recommend Easing Restrictions on Marijuana**
- The move would kick off a lengthy rule-making process and would amount to a major change in federal policy.



College on Problems of Drug Dependence Friends of the National Institute on Drug Abuse Senator Tim Kaine (VA)

50th Anniversary *of the* National Institute on Drug Abuse

Tuesday, May 14, 2024

4:00-6:00 pm

Kennedy Caucus Room

325 Russell Senate Office Building



Nora Volkow, MD
Director
National Institute on Drug Abuse



Jeremy M. Byard
CARE@Arthur Street Hotel



Sandra Comer, PhD
Columbia University Medical Center



Gail D'Onofrio, MD, MS
Yale School of Medicine



Hansel Tookes, MD, MPH
University of Miami Miller School of
Medicine

Thank you!

N-CREW

Phase I Development and Planning


FY24-25 \$~25 million

- ROA OTA 23-007: **T/NASOs** plan, develop, pilot, and/or implement research and/or data improvement projects.
- ROA OTA 23-008: T/NASOs and Ally Organizations form a **Native Research Resource Network (NRRN)** to provide training, resources and program coordination.

Phase II will build on Phase I

FY26-30 \$~240 million

Contact: NCREW@NIH.GOV



T/NASOs: Tribes and Native American Serving Organizations